A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2011

Molecules

Volumn 18, Issue 4, 2013, Pages 3641-3673

  Sawadogo, Wamtinga Richard ^a,b   Schumacher, Marc ^a   Teiten, Marie Hélène ^a   Cerella, Claudia ^a   Dicato, Mario ^a   Diederich, Marc ^c  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

^b Public Health Research Institute for Health Sciences   (Burkina Faso)

^c Seoul National University   (South Korea)

Author keywords

Anticancer molecules; Cancer; Marine origin; Synthetic derivatives

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT;

ANIMAL; AQUATIC SPECIES; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; HUMAN; ISOLATION AND PURIFICATION; NEOPLASM; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; AQUATIC ORGANISMS; BIOLOGICAL AGENTS; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84876767778     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18043641     Document Type: Review

References (138)

1. IARC. Cancer Incidence and Mortality Worlwide; International Agency for Research on Cancer: Lyon, France, 2011.
2. WHO. Global Status Report on Noncommunicable Diseases 2010; WT 500; WHO: Geneva, Switzerland, 2011.
3. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893-2917.
4. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75, 311-335.
5. Sarfaraj, H.M.; Sheeba, F.; Saba, A.; Mohd, S.K. Marine natural products: A lead for anti-cancer. Indian J. Mar. Sci. 2012, 41, 27-39.
6. Newman, D.J.; Cragg, G.M. Marine natural products and related compounds in clinical and advanced preclinical trials. J. Nat. Prod. 2004, 67, 1216-1238.
7. Benkendorff, K. Molluscan biological and chemical diversity: Secondary metabolites and medicinal resources produced by marine molluscs. Biol. Rev. 2010, 85, 757-775.
8. Nastrucci, C.; Cesario, A.; Russo, P. Anticancer drug discovery from the marine environment. Recent Pat. Anticancer Drug Discov. 2012, 7, 218-232.
9. Schumacher, M.; Kelkel, M.; Dicato, M.; Diederich, M. A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2010. Molecules 2011, 16, 5629-5646.
10. Nakamura, H.; Wu, H.; Ohizumi, Y.; Hirata, Y. Agelasine-A, -B, -C and -D, novel bicyclic diterpenoids with a 9-methyladeninium unit possessing inhibitory effects on na,K-atpase from the okinawa sea sponge Agelas sp.1). Tetrahedron Lett. 1984, 25, 2989-2992.
11. Roggen, H.; Charnock, C.; Burman, R.; Felth, J.; Larsson, R.; Bohlin, L.; Gundersen, L.L. Antimicrobial and antineoplastic activities of agelasine analogs modified in the purine 2-position. Arch. Pharm. (Weinheim) 2011, 344, 50-55.
12. Yan, X.; Chen, H.; Lu, X.; Wang, F.; Xu, W.; Jin, H.; Zhu, P. Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model. Eur. J. Pharm. Sci. 2011, 43, 251-259.
13. Segraves, N.L.; Lopez, S.; Johnson, T.A.; Said, S.A.; Fu, X.; Schmitz, F.J.; Pietraszkiewicz, H.; Valeriote, F.A.; Crews, P. Structures and cytotoxicities of fascaplysin and related alkaloids from two marine phyla - Fascaplysinopsis sponges and Didemnum tunicates. Tetrahedron Lett. 2003, 44, 3471-3475.
14. Segraves, N.L.; Robinson, S.J.; Garcia, D.; Said, S.A.; Fu, X.; Schmitz, F.J.; Pietraszkiewicz, H.; Valeriote, F.A.; Crews, P. Comparison of fascaplysin and related alkaloids: A study of structures, cytotoxicities, and sources. J. Nat. Prod. 2004, 67, 783-792.
15. Lin, J.; Yan, X.J.; Chen, H.M. Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo. Cancer Chemother. Pharmacol. 2007, 59, 439-445.
16. Zheng, Y.L.; Lu, X.L.; Lin, J.; Chen, H.M.; Yan, X.J.; Wang, F.; Xu, W.F. Direct effects of fascaplysin on human umbilical vein endothelial cells attributing the anti-angiogenesis activity. Biomed. Pharmacother. 2010, 64, 527-533.
17. Hormann, A.; Chaudhuri, B.; Fretz, H. DNA binding properties of the marine sponge pigment fascaplysin. Bioorg. Med. Chem. 2001, 9, 917-921.
18. Lu, X.L.; Zheng, Y.L.; Chen, H.M.; Yan, X.J.; Wang, F.; Xu, W.F. Anti-proliferation of human cervical cancer HeLa cell line by fascaplysin through apoptosis induction. Yao Xue Xue Bao 2009, 44, 980-986.
19. Shafiq, M.I.; Steinbrecher, T.; Schmid, R. Fascaplysin as a specific inhibitor for CDK4: Insights from molecular modelling. PLoS One 2012, 7, e42612.
20. Wang, W.; Rayburn, E.R.; Velu, S.E.; Nadkarni, D.H.; Murugesan, S.; Zhang, R. In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin. Cancer Res. 2009, 15, 3511-3518.
21. Shinkre, B.A.; Raisch, K.P.; Fan, L.; Velu, S.E. Synthesis and antiproliferative activity of benzyl and phenethyl analogs of makaluvamines. Bioorg. Med. Chem. 2008, 16, 2541-2549.
22. Chen, T.; Xu, Y.; Guo, H.; Liu, Y.; Hu, P.; Yang, X.; Li, X.; Ge, S.; Velu, S.E.; Nadkarni, D.H.; et al. Experimental therapy of ovarian cancer with synthetic makaluvamine analog: In vitro and in vivo anticancer activity and molecular mechanisms of action. PLoS One 2011, 6, e20729.
23. Ocio, E.M.; Maiso, P.; Chen, X.; Garayoa, M.; Alvarez-Fernandez, S.; San-Segundo, L.; Vilanova, D.; Lopez-Corral, L.; Montero, J.C.; Hernandez-Iglesias, T.; et al. Zalypsis: A novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 2009, 113, 3781-3791.
24. Leal, J.F.; Garcia-Hernandez, V.; Moneo, V.; Domingo, A.; Bueren-Calabuig, J.A.; Negri, A.; Gago, F.; Guillen-Navarro, M.J.; Aviles, P.; Cuevas, C.; et al. Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. Biochem. Pharmacol. 2009, 78, 162-170.
25. Colado, E.; Paino, T.; Maiso, P.; Ocio, E.M.; Chen, X.; Alvarez-Fernandez, S.; Gutierrez, N.C.; Martin-Sanchez, J.; Flores-Montero, J.; San Segundo, L.; et al. Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica 2011, 96, 687-695.
26. Massard, C.; Margetts, J.; Amellal, N.; Drew, Y.; Bahleda, R.; Stevens, P.; Armand, J.P.; Calvert, H.; Soria, J.C.; Coronado, C.; et al. Phase I study of PM00104 (Zalypsis ®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors. Invest. New Drugs 2012, doi:10.1007/s10637-012-9843-5.
27. Yap, T.A.; Cortes-Funes, H.; Shaw, H.; Rodriguez, R.; Olmos, D.; Lal, R.; Fong, P.C.; Tan, D.S.; Harris, D.; Capdevila, J.; et al. First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours. Br. J. Cancer 2012, 106, 1379-1385.
28. Perez-Ruixo, C.; Valenzuela, B.; Fernandez Teruel, C.; Gonzalez-Sales, M.; Miguel-Lillo, B.; Soto-Matos, A.; Perez-Ruixo, J.J. Population pharmacokinetics of PM00104 (Zalypsis((R))) in cancer patients. Cancer Chemother. Pharmacol. 2012, 69, 15-24.
29. Jiang, G.C.; Lin, Y.C.; Zhou, S.N.; Vrumoed, I.I.P.; Jones, E.B.G. Study on the secondary metabolites of mangrove fungus N° 1403 from the South China Sea. Acta Sci. Natur. Univ. Sunyatseni 2000, 39, 68-72.
30. Zhang, J.Y.; Tao, L.Y.; Liang, Y.J.; Chen, L.M.; Mi, Y.J.; Zheng, L.S.; Wang, F.; She, Z.G.; Lin, Y.C.; To, K.K.; et al. Anthracenedione derivatives as anticancer agents isolated from secondary metabolites of the mangrove endophytic fungi. Mar. Drugs 2010, 8, 1469-1481.
31. Yuan, J.; He, Z.; Wu, J.; Lin, Y.; Zhu, X. A novel adriamycin analogue derived from marine microbes induces apoptosis by blocking Akt activation in human breast cancer cells. Mol. Med. Report. 2011, 4, 261-265.
32. Chin, P.C.; D'Mello, S.R. Survival of cultured cerebellar granule neurons can be maintained by Akt-dependent and Akt-independent signaling pathways. Mol. Brain Res. 2004, 127, 140-145.
33. Lee, S.; Choi, E.J.; Jin, C.; Kim, D.H. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol. Oncol. 2005, 97, 26-34.
34. Fujiwara, Y.; Kawada, K.; Takano, D.; Tanimura, S.; Ozaki, K.-I.; Kohno, M. Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner. Biochem. Biophys. Res. Commun. 2006, 340, 560-566.
35. West, K.A.; Sianna Castillo, S.; Dennis, P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat. 2002, 5, 234-248.
36. LoPiccolo, J.; Blumenthal, G.M.; Bernstein, W.B.; Dennis, P.A. Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resist. Updat. 2008, 11, 32-50.
37. Chen, W.S.; Hou, J.N.; Guo, Y.B.; Yang, H.L.; Xie, C.M.; Lin, Y.C.; She, Z.G. Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K/Akt pathway. J. Exp. Clin. Cancer Res. 2011, 30, doi:10.1186/1756-9966-30-17.
38. Hu, Y.; MacMillan, J.B. Erythrazoles A-B, cytotoxic benzothiazoles from a marine-derived Erythrobacter sp. Org. Lett. 2011, 13, 6580-6583.
39. Chen, Q.Y.; Liu, Y.; Luesch, H. Systematic chemical mutagenesis identifies a potent novel apratoxin A/E hybrid with improved in vivo antitumor activity. ACS Med. Chem. Lett. 2011, 2, 861-865.
40. Baselga, J. Targeting tyrosine kinases in cancer: The second wave. Science 2006, 312, 1175-1178.
41. Kerbel, R.S. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000, 21, 505-515.
42. Matthew, S.; Schupp, P.J.; Luesch, H. Apratoxin E, a cytotoxic peptolide from a guamanian collection of the marine cyanobacterium Lyngbya bouillonii. J. Nat. Prod. 2008, 71, 1113-1116.
43. Ma, D.; Zou, B.; Cai, G.; Hu, X.; Liu, J.O. Total synthesis of the cyclodepsipeptide apratoxin A and its analogues and assessment of their biological activities. Chemistry 2006, 12, 7615-7626.
44. Doi, T.; Numajiri, Y.; Takahashi, T.; Takagi, M.; Shin-ya, K. Solid-phase total synthesis of (-)-apratoxin A and its analogues and their biological evaluation. Chem. Asian J. 2011, 6, 180-188.
45. Kito, K.; Ookura, R.; Yoshida, S.; Namikoshi, M.; Ooi, T.; Kusumi, T. New cytotoxic 14-membered macrolides from marine-derived fungus Aspergillus ostianus. Org. Lett. 2008, 10, 225-228.
46. Diaz-Oltra, S.; Angulo-Pachon, C.A.; Murga, J.; Falomir, E.; Carda, M.; Marco, J.A. Synthesis and biological properties of the cytotoxic 14-membered macrolides aspergillide A and B. Chemistry 2011, 17, 675-688.
47. Hu, Y.; Espindola, A.P.; Stewart, N.A.; Wei, S.; Posner, B.A.; MacMillan, J.B. Chromomycin SA analogs from a marine-derived Streptomyces sp. Bioorg. Med. Chem. 2011, 19, 5183-5189.
48. Menendez, N.; Nur-e-Alam, M.; Brana, A.F.; Rohr, J.; Salas, J.A.; Mendez, C. Biosynthesis of the antitumor chromomycin A3 in Streptomyces griseus: analysis of the gene cluster and rational design of novel chromomycin analogs. Chem. Biol. 2004, 11, 21-32.
49. Wei, R.B.; Xi, T.; Li, J.; Wang, P.; Li, F.C.; Lin, Y.C.; Qin, S. Lobophorin C and D, new kijanimicin derivatives from a marine sponge-associated actinomycetal strain AZS17. Mar. Drugs 2011, 9, 359-368.
50. Paterson, I.; Coster, M.J. Chapter 8 Total synthesis of spongistatin 1 (altohyrtin a): A tale of ten aldols. In Strategies and Tactics in Organic Synthesis; Michael, H., Ed.; Academic Press: Oxford, UK, 2004; Volume 4, pp. 211-245.
51. Smith Iii, A.B.; Sfouggatakis, C.; Risatti, C.A.; Sperry, J.B.; Zhu, W.; Doughty, V.A.; Tomioka, T.; Gotchev, D.B.; Bennett, C.S.; Sakamoto, S.; et al. Spongipyran synthetic studies. Evolution of a scalable total synthesis of (+)-spongistatin 1. Tetrahedron 2009, 65, 6489-6509.
52. Bai, R.; Cichacz, Z.A.; Herald, C.L.; Pettit, G.R.; Hamel, E. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin. Mol. Pharmacol. 1993, 44, 757-766.
53. Paterson, I.; Chen, D.Y.; Coster, M.J.; Acena, J.L.; Bach, J.; Wallace, D.J. The stereocontrolled total synthesis of altohyrtin A/spongistatin 1: Fragment couplings, completion of the synthesis, analogue generation and biological evaluation. Org. Biomol. Chem. 2005, 3, 2431-2440.
54. Rothmeier, A.S.; Schneiders, U.M.; Wiedmann, R.M.; Ischenko, I.; Bruns, C.J.; Rudy, A.; Zahler, S.; Vollmar, A.M. The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis. Int. J. Cancer 2010, 127, 1096-1105.
55. Schneiders, U.M.; Schyschka, L.; Rudy, A.; Vollmar, A.M. BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells. Mol. Cancer Ther. 2009, 8, 2914-2925.
56. Schyschka, L.; Rudy, A.; Jeremias, I.; Barth, N.; Pettit, G.R.; Vollmar, A.M. Spongistatin 1: A new chemosensitizing marine compound that degrades XIAP. Leukemia 2008, 22, 1737-1745.
57. Xu, Q.; Huang, K.C.; Tendyke, K.; Marsh, J.; Liu, J.; Qiu, D.; Littlefield, B.A.; Nomoto, K.; Atasoylu, O.; Risatti, C.A.; et al. In vitro and in vivo anticancer activity of (+)-spongistatin 1. Anticancer Res. 2011, 31, 2773-2779.
58. Choi, E.J.; Park, J.S.; Kim, Y.J.; Jung, J.H.; Lee, J.K.; Kwon, H.C.; Yang, H.O. Apoptosisinducing effect of diketopiperazine disulfides produced by Aspergillus sp. KMD 901 isolated from marine sediment on HCT116 colon cancer cell lines. J. Appl. Microbiol. 2011, 110, 304-313.
59. Gardiner, D.M.; Waring, P.; Howlett, B.J. The epipolythiodioxopiperazine (ETP) class of fungal toxins: Distribution, mode of action, functions and biosynthesis. Microbiology 2005, 151, 1021-1032.
60. Hadaschik, B.A.; Adomat, H.; Fazli, L.; Fradet, Y.; Andersen, R.J.; Gleave, M.E.; So, A.I. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin. Clin. Cancer Res. 2008, 14, 1510-1518.
61. Loganzo, F.; Discafani, C.M.; Annable, T.; Beyer, C.; Musto, S.; Hari, M.; Tan, X.; Hardy, C.; Hernandez, R.; Baxter, M.; et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 2003, 63, 1838-1845.
62. Kuznetsov, G.; TenDyke, K.; Towle, M.J.; Cheng, H.; Liu, J.; Marsh, J.P.; Schiller, S.E.; Spyvee, M.R.; Yang, H.; Seletsky, B.M.; et al. Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Mol. Cancer Ther. 2009, 8, 2852-2860.
63. Hsu, L.C.; Durrant, D.E.; Huang, C.C.; Chi, N.W.; Baruchello, R.; Rondanin, R.; Rullo, C.; Marchetti, P.; Grisolia, G.; Simoni, D.; et al. Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor. Invest. New Drugs 2012, 30, 1379-1388.
64. Watts, K.R.; Morinaka, B.I.; Amagata, T.; Robinson, S.J.; Tenney, K.; Bray, W.M.; Gassner, N.C.; Lokey, R.S.; Media, J.; Valeriote, F.A.; et al. Biostructural features of additional jasplakinolide (jaspamide) analogues. J. Nat. Prod. 2011, 74, 341-351.
65. Tannert, R.; Milroy, L.G.; Ellinger, B.; Hu, T.S.; Arndt, H.D.; Waldmann, H. Synthesis and structure-activity correlation of natural-product inspired cyclodepsipeptides stabilizing F-actin. J. Am. Chem. Soc. 2010, 132, 3063-3077.
66. Tan, L.T.; Chang, Y.Y.; Ashootosh, T. Besarhanamides A and B from the marine cyanobacterium Lyngbya majuscula. Phytochemistry 2008, 69, 2067-2069.
67. Tripathi, A.; Puddick, J.; Prinsep, M.R.; Rottmann, M.; Chan, K.P.; Chen, D.Y.; Tan, L.T. Lagunamide C, a cytotoxic cyclodepsipeptide from the marine cyanobacterium Lyngbya majuscula. Phytochemistry 2011, 72, 2369-2375.
68. Duffy, R.; Wade, C.; Chang, R. Discovery of anticancer drugs from antimalarial natural products: a MEDLINE literature review. Drug Discov. Today 2012, 17, 942-953.
69. Hirata, A.; Guan, P.; Fujita, T.; Hirotsu, Y.; Inoue, A.; Yavari, A.R.; Sakurai, T.; Chen, M. Direct observation of local atomic order in a metallic glass. Nat. Mater. 2011, 10, 28-33.
70. Cole, K.E.; Dowling, D.P.; Boone, M.A.; Phillips, A.J.; Christianson, D.W. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J. Am. Chem. Soc. 2011, 133, 12474-12477.
71. Wang, B.; Huang, P.H.; Chen, C.S.; Forsyth, C.J. Total syntheses of the histone deacetylase inhibitors largazole and 2-epi-largazole: application of N-heterocyclic carbene mediated acylations in complex molecule synthesis. J. Org. Chem. 2011, 76, 1140-1150.
72. Benelkebir, H.; Marie, S.; Hayden, A.L.; Lyle, J.; Loadman, P.M.; Crabb, S.J.; Packham, G.; Ganesan, A. Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability. Bioorg. Med. Chem. 2011, 19, 3650-3658.
73. Bhansali, P.; Hanigan, C.L.; Casero, R.A.; Tillekeratne, L.M. Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: Synthesis and biological evaluation. J. Med. Chem. 2011, 54, 7453-7463.
74. Mwakwari, S.C.; Patil, V.; Guerrant, W.; Oyelere, A.K. Macrocyclic histone deacetylase inhibitors. Curr. Top. Med. Chem. 2010, 10, 1423-1440.
75. Raju, R.; Piggott, A.M.; Huang, X.C.; Capon, R.J. Nocardioazines: A novel bridged diketopiperazine scaffold from a marine-derived bacterium inhibits P-glycoprotein. Org. Lett. 2011, 13, 2770-2773.
76. Huang, T.C.; Lee, J.F.; Chen, J.Y. Pardaxin, an antimicrobial peptide, triggers caspase-dependent and ROS-mediated apoptosis in HT-1080 cells. Mar. Drugs 2011, 9, 1995-2009.
77. Hsu, J.C.; Lin, L.C.; Tzen, J.T.; Chen, J.Y. Pardaxin-induced apoptosis enhances antitumor activity in HeLa cells. Peptides 2011, 32, 1110-1116.
78. Makarieva, T.N.; Guzii, A.G.; Denisenko, V.A.; Dmitrenok, P.S.; Santalova, E.A.; Pokanevich, E.V.; Molinski, T.F.; Stonik, V.A. Rhizochalin A, a novel two-headed sphingolipid from the sponge Rhizochalina incrustata. J. Nat. Prod. 2005, 68, 255-257.
79. Khanal, P.; Kang, B.S.; Yun, H.J.; Cho, H.G.; Makarieva, T.N.; Choi, H.S. Aglycon of rhizochalin from the Rhizochalina incrustata induces apoptosis via activation of AMP-activated protein kinase in HT-29 colon cancer cells. Biol. Pharm. Bull. 2011, 34, 1553-1558.
80. Fedorov, S.N.; Makarieva, T.N.; Guzii, A.G.; Shubina, L.K.; Kwak, J.Y.; Stonik, V.A. Marine two-headed sphingolipid-like compound rhizochalin inhibits EGF-induced transformation of JB6 P+ Cl41 cells. Lipids 2009, 44, 777-785.
81. Jin, J.O.; Shastina, V.; Park, J.I.; Han, J.Y.; Makarieva, T.; Fedorov, S.; Rasskazov, V.; Stonik, V.; Kwak, J.Y. Differential induction of apoptosis of leukemic cells by rhizochalin, two headed sphingolipids from sponge and its derivatives. Biol. Pharm. Bull. 2009, 32, 955-962.
82. Lerdrup, M.; Holmberg, C.; Dietrich, N.; Shaulian, E.; Herdegen, T.; Jäättelä, M.; Kallunki, T. Depletion of the AP-1 repressor JDP2 induces cell death similar to apoptosis. Biochim. Biophys. Acta 2005, 1745, 29-37.
83. Shaulian, E. AP-1 - The Jun proteins: Oncogenes or tumor suppressors in disguise? Cell. Signal. 2010, 22, 894-899.
84. Jiang, Y.; Miao, Z.H.; Xu, L.; Yu, B.; Gong, J.X.; Tong, L.J.; Chen, Y.; Zhou, Z.L.; Liu, H.C.; Wang, Y.; et al. Drug transporter-independent liver cancer cell killing by a marine steroid methyl spongoate via apoptosis induction. J. Biol. Chem. 2011, 286, 26461-26469.
85. Papatheodoridis, G.V.; Lampertico, P.; Manolakopoulos, S.; Lok, A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. J. Hepatol. 2010, 53, 348-356.
86. Thomas, M. Molecular targeted therapy for hepatocellular carcinoma. J. Gastroenterol. 2009, 44, 136-141.
87. Al Zaid Siddiquee, K.; Turkson, J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008, 18, 254-267.
88. Masuda, M.; Wakasaki, T.; Suzui, M.; Toh, S.; Joe, A.K.; Weinstein, I.B. Stat3 orchestrates tumor development and progression: The Achilles' heel of head and neck cancers? Curr. Cancer Drug Targets 2010, 10, 117-126.
89. Zhang, C.; Li, Y.; Qian, Z.J.; Lee, S.H.; Li, Y.X.; Kim, S.K. Dieckol from ecklonia cava regulates invasion of human fibrosarcoma cells and modulates MMP-2 and MMP-9 expression via NF-kappaB pathway. Evid. Based Complement. Alternat. Med. 2011, 2011, 140462.
90. Das, S.; Banerji, A.; Frei, E.; Chatterjee, A. Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium. Life Sci. 2008, 82, 467-476.
91. Baker, A.H.; Edwards, D.R.; Murphy, G. Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J. Cell. Sci. 2002, 115, 3719-3727.
92. Tanimura, S.; Kadomoto, R.; Tanaka, T.; Zhang, Y.J.; Kouno, I.; Kohno, M. Suppression of tumor cell invasiveness by hydrolyzable tannins (plant polyphenols) via the inhibition of matrix metalloproteinase-2/-9 activity. Biochem. Biophys. Res. Commun. 2005, 330, 1306-1313.
93. Park, S.J.; Jeon, Y.J. Dieckol from Ecklonia cava suppresses the migration and invasion of HT1080 cells by inhibiting the focal adhesion kinase pathway downstream of Rac1-ROS signaling. Mol. Cells 2012, 33, 141-149.
94. Lee, J.; Jung, E.; Lee, J.; Huh, S.; Hwang, C.H.; Lee, H.Y.; Kim, E.J.; Cheon, J.M.; Hyun, C.G.; Kim, Y.S.; et al. Emodin inhibits TNF alpha-induced MMP-1 expression through suppression of activator protein-1 (AP-1). Life Sci. 2006, 79, 2480-2485.
95. Fassett, R.G.; Coombes, J.S. Astaxanthin: A potential therapeutic agent in cardiovascular disease. Mar. Drugs 2011, 9, 447-465.
96. Choi, H.D.; Kim, J.H.; Chang, M.J.; Kyu-Youn, Y.; Shin, W.G. Effects of astaxanthin on oxidative stress in overweight and obese adults. Phytother. Res. 2011, 25, 1813-1818.
97. Palozza, P.; Torelli, C.; Boninsegna, A.; Simone, R.; Catalano, A.; Mele, M.C.; Picci, N. Growth-inhibitory effects of the astaxanthin-rich alga Haematococcus pluvialis in human colon cancer cells. Cancer Lett. 2009, 283, 108-117.
98. Wolf, A.M.; Asoh, S.; Hiranuma, H.; Ohsawa, I.; Iio, K.; Satou, A.; Ishikura, M.; Ohta, S. Astaxanthin protects mitochondrial redox state and functional integrity against oxidative stress. J. Nutr. Biochem. 2010, 21, 381-389.
99. Nagendraprabhu, P.; Sudhandiran, G. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2. Invest. New Drugs 2011, 29, 207-224.
100. Prabhu, P.N.; Ashokkumar, P.; Sudhandiran, G. Antioxidative and antiproliferative effects of astaxanthin during the initiation stages of 1,2-dimethyl hydrazine-induced experimental colon carcinogenesis. Fundam. Clin. Pharmacol. 2009, 23, 225-234.
101. Yasui, Y.; Hosokawa, M.; Mikami, N.; Miyashita, K.; Tanaka, T. Dietary astaxanthin inhibits colitis and colitis-associated colon carcinogenesis in mice via modulation of the inflammatory cytokines. Chem. Biol. Interact. 2011, 193, 79-87.
102. Pahl, H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18, 6853-6866.
103. Karin, M.; Greten, F.R. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5, 749-759.
104. Lee, N.L.; Su, J.H. Tetrahydrofuran cembranoids from the cultured soft coral Lobophytum crassum. Mar. Drugs 2011, 9, 2526-2536.
105. Ebada, S.S.; Lin, W.; Proksch, P. Bioactive sesterterpenes and triterpenes from marine sponges: Occurrence and pharmacological significance. Mar. Drugs 2010, 8, 313-346.
106. Piao, S.J.; Zhang, H.J.; Lu, H.Y.; Yang, F.; Jiao, W.H.; Yi, Y.H.; Chen, W.S.; Lin, H.W. Hippolides A-H, acyclic manoalide derivatives from the marine sponge Hippospongia lachne. J. Nat. Prod. 2011, 74, 1248-1254.
107. Shen, Y.-C.; Lo, K.-L.; Lin, Y.-C.; Khalil, A.T.; Kuo, Y.-H.; Shih, P.-S. Novel linear C22-sesterterpenoids from sponge Ircinia formosana. Tetrahedron Lett. 2006, 47, 4007-4010.
108. Su, J.H.; Tseng, S.W.; Lu, M.C.; Liu, L.L.; Chou, Y.; Sung, P.J. Cytotoxic C21 and C22 terpenoid-derived metabolites from the sponge Ircinia sp. J. Nat. Prod. 2011, 74, 2005-2009.
109. Su, J.H.; Chang, W.B.; Chen, H.M.; El-Shazly, M.; Du, Y.C.; Kung, T.H.; Chen, Y.C.; Sung, P.J.; Ho, Y.S.; Kuo, F.W.; et al. 10-acetylirciformonin B, a sponge furanoterpenoid, induces DNA damage and apoptosis in leukemia cells. Molecules 2012, 17, 11839-11848.
110. Wright, A.D.; Wang, H.; Gurrath, M.; Konig, G.M.; Kocak, G.; Neumann, G.; Loria, P.; Foley, M.; Tilley, L. Inhibition of heme detoxification processes underlies the antimalarial activity of terpene isonitrile compounds from marine sponges. J. Med. Chem. 2001, 44, 873-885.
111. Lamoral-Theys, D.; Fattorusso, E.; Mangoni, A.; Perinu, C.; Kiss, R.; Costantino, V. Evaluation of the antiproliferative activity of diterpene isonitriles from the sponge Pseudoaxinella flava in apoptosis-sensitive and apoptosis-resistant cancer cell lines. J. Nat. Prod. 2011, 74, 2299-2303.
112. Lin, W.Y.; Lu, Y.; Su, J.H.; Wen, Z.H.; Dai, C.F.; Kuo, Y.H.; Sheu, J.H. Bioactive cembranoids from the dongsha atoll soft coral Sarcophyton crassocaule. Mar. Drugs 2011, 9, 994-1006.
113. Hassan, H.M.; Sallam, A.A.; Mohammed, R.; Hifnawy, M.S.; Youssef, D.T.; El Sayed, K.A. Semisynthetic analogues of the marine cembranoid sarcophine as prostate and breast cancer migration inhibitors. Bioorg. Med. Chem. 2011, 19, 4928-4934.
114. Ganesan, P.; Noda, K.; Manabe, Y.; Ohkubo, T.; Tanaka, Y.; Maoka, T.; Sugawara, T.; Hirata, T. Siphonaxanthin, a marine carotenoid from green algae, effectively induces apoptosis in human leukemia (HL-60) cells. Biochim. Biophys. Acta 2011, 1810, 497-503.
115. Ganesan, P.; Matsubara, K.; Ohkubo, T.; Tanaka, Y.; Noda, K.; Sugawara, T.; Hirata, T. Anti-angiogenic effect of siphonaxanthin from green alga, Codium fragile. Phytomedicine 2010, 17, 1140-1144.
116. Kong, D.; Aoki, S.; Sowa, Y.; Sakai, T.; Kobayashi, M. Smenospongine, a sesquiterpene aminoquinone from a marine sponge, induces G1 arrest or apoptosis in different leukemia cells. Mar. Drugs 2008, 6, 480-488.
117. Aoki, S.; Kong, D.; Matsui, K.; Kobayashi, M. Smenospongine, a spongean sesquiterpene aminoquinone, induces erythroid differentiation in K562 cells. Anticancer Drug 2004, 15, 363-369.
118. Kong, D.; Yamori, T.; Kobayashi, M.; Duan, H. Antiproliferative and antiangiogenic activities of smenospongine, a marine sponge sesquiterpene aminoquinone. Mar. Drugs 2011, 9, 154-161.
119. Coval, S.J.; Scheuer, P.J.; Matsumoto, G.K.; Clardy, J. Two new xenicin diterpenoids from the octocoral anthelia edmondsoni. Tetrahedron 1984, 40, 3823-3828.
120. Zierler, S.; Yao, G.; Zhang, Z.; Kuo, W.C.; Porzgen, P.; Penner, R.; Horgen, F.D.; Fleig, A. Waixenicin A inhibits cell proliferation through magnesium-dependent block of transient receptor potential melastatin 7 (TRPM7) channels. J. Biol. Chem. 2011, 286, 39328-39335.
121. Guilbert, A.; Gautier, M.; Dhennin-Duthille, I.; Haren, N.; Sevestre, H.; Ouadid-Ahidouch, H. Evidence that TRPM7 is required for breast cancer cell proliferation. Am. J. Physiol. Cell. Physiol. 2009, 297, C493-C502.
122. Dhennin-Duthille, I.; Gautier, M.; Faouzi, M.; Guilbert, A.; Brevet, M.; Vaudry, D.; Ahidouch, A.; Sevestre, H.; Ouadid-Ahidouch, H. High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: Correlation with pathological parameters. Cell. Physiol. Biochem. 2011, 28, 813-822.
123. Jiang, J.; Li, M.H.; Inoue, K.; Chu, X.P.; Seeds, J.; Xiong, Z.G. Transient receptor potential melastatin 7-like current in human head and neck carcinoma cells: Role in cell proliferation. Cancer Res. 2007, 67, 10929-10938.
124. Kim, B.J.; Park, E.J.; Lee, J.H.; Jeon, J.H.; Kim, S.J.; So, I. Suppression of transient receptor potential melastatin 7 channel induces cell death in gastric cancer. Cancer Sci. 2008, 99, 2502-2509.
125. Paravicini, T.M.; Chubanov, V.; Gudermann, T. TRPM7: A unique channel involved in magnesium homeostasis. Int. J. Biochem. Cell. Biol. 2012, 44, 1381-1384.
126. Li, M.; Du, J.; Jiang, J.; Ratzan, W.; Su, L.T.; Runnels, L.W.; Yue, L. Molecular determinants of Mg2+ and Ca2+ permeability and pH sensitivity in TRPM6 and TRPM7. J. Biol. Chem. 2007, 282, 25817-25830.
127. Li, M.; Jiang, J.; Yue, L. Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. J. Gen. Physiol. 2006, 127, 525-537.
128. Ryazanova, L.V.; Rondon, L.J.; Zierler, S.; Hu, Z.; Galli, J.; Yamaguchi, T.P.; Mazur, A.; Fleig, A.; Ryazanov, A.G. TRPM7 is essential for Mg2+ homeostasis in mammals. Nat. Commun. 2010, 1, doi:10.1038/ncomms1108.
129. Schmitz, C.; Perraud, A.L.; Johnson, C.O.; Inabe, K.; Smith, M.K.; Penner, R.; Kurosaki, T.; Fleig, A.; Scharenberg, A.M. Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7. Cell 2003, 114, 191-200.
130. Schmitz, C.; Perraud, A.L.; Fleig, A.; Scharenberg, A.M. Dual-function ion channel/protein kinases: novel components of vertebrate magnesium regulatory mechanisms. Pediatr. Res. 2004, 55, 734-737.
131. Cappadone, C.; Merolle, L.; Marraccini, C.; Farruggia, G.; Sargenti, A.; Locatelli, A.; Morigi, R.; Iotti, S. Intracellular magnesium content decreases during mitochondria-mediated apoptosis induced by a new indole-derivative in human colon cancer cells. Magnes. Res. 2012, 25, 104-111.
132. Wolf, F.I.; Trapani, V. Magnesium and its transporters in cancer: A novel paradigm in tumour development. Clin. Sci. 2012, 123, 417-427.
133. Chen, J.P.; Luan, Y.; You, C.X.; Chen, X.H.; Luo, R.C.; Li, R. TRPM7 regulates the migration of human nasopharyngeal carcinoma cell by mediating Ca2+ influx. Cell Calcium 2010, 47, 425-432.
134. Carvalho, M.; Ferreira, P.J.; Mendes, V.S.; Silva, R.; Pereira, J.A.; Jerónimo, C.; Silva, B.M. Human cancer cell antiproliferative and antioxidant activities of Juglans regia L. Food Chem. Toxicol. 2010, 48, 441-447.
135. Dia, V.P.; Gonzalez de Mejia, E. Lunasin potentiates the effect of oxaliplatin preventing outgrowth of colon cancer metastasis, binds to α5β1 integrin and suppresses FAK/ERK/NF-κB signaling. Cancer Lett. 2011, 313, 167-180.
136. Rea, G.; Antonacci, A.; Lambreva, M.; Pastorelli, S.; Tibuzzi, A.; Ferrari, S.; Fischer, D.; Johanningmeier, U.; Oleszek, W.; Doroszewska, T.; et al. Integrated plant biotechnologies applied to safer and healthier food production: The Nutra-Snack manufacturing chain. Trends Food Sci. Technol. 2011, 22, 353-366.
137. Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
138. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46, 3-26.